• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BioXcel Therapeutics Inc.

    4/4/25 4:16:14 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email
    S-8 1 tm2511409d1_s8.htm FORM S-8

     

     

    As filed with the Securities and Exchange Commission on April 4, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    BioXcel Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-1386754

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    555 Long Wharf Drive

    New Haven, CT 06511

    (Address of Principal Executive Offices) (Zip Code)

     

    BioXcel Therapeutics, Inc. 2020 Incentive Award Plan

    BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Vimal Mehta, Ph.D.
    Chief Executive Officer
    BioXcel Therapeutics, Inc.
    555 Long Wharf Drive
    New Haven, CT 06511
    (Name and address of agent for service)

     

    (475) 238-6837

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    N. Danny Shulman

    Emily Johns

    Honigman LLP

    1440 New York Avenue, NW Suite 200

    Washington, DC 20005

    (202) 844 3380

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    This Registration Statement on Form S-8 is being filed with the U.S. Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 155,120 shares of common stock, par value $0.001 per share (the “Common Stock”), of BioXcel Therapeutics, Inc. (the “Company”), issuable under the following employee benefit plans for which a registration statement of the Company on Form S-8 (File Nos. 333-238580, 333-266922, 333-270652 and 333-278492) is effective: (i) the BioXcel Therapeutics, Inc. 2020 Incentive Award Plan (the “2020 Plan”) and (ii) the BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”). Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference herein.

     

    INCORPORATION BY REFERENCE

     

    The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

     

    • Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025.

     

    • Our Current Reports on Form 8-K, filed with the SEC on January 8, 2025, January 16, 2025, January 29, 2025, February 6, 2025, March 3, 2025, March 4, 2025, March 21, 2025 and March 21, 2025.

     

    • The description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on March 5, 2018, as updated by “Description of the Registrant’s Securities Registered under Section 12 of the Exchange Act” filed as Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and any amendment or report filed with the SEC for the purpose of updating such description.

     

    In addition, all reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the “Exchange Act” in this prospectus, prior to the termination of this offering, including all such documents we may file with the SEC after the date of filing of this registration statement and prior to the effectiveness of this registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

     

    Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

     

     

     

    Item 8. EXHIBITS.

     

    Exhibit           Incorporated by
    Reference
           
    Number   Exhibit Description   Form   File
    Number
      Filing
    Date
      Exhibit   Filed
    Herewith
                   
      3.1   Amended and Restated Certificate of Incorporation   10-Q   001-38410   8-10-2021   3.1    
                   
      3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation   8-K   001-38410   6-12-2024   3.1    
                   
      3.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation   8-K   001-38410   2-6-2025   3.1    
                               
      3.4   Amended and Restated Bylaws   8-K   001-38410   3-13-2018   3.2    
                   
      3.5   Specimen Stock Certificate evidencing the shares of common stock.   S-1/A   333-22990   2-26-2018   4.2    
                               
      5.1   Opinion of Honigman LLP                   *
                               
      23.1   Consent of Ernst & Young LLP, independent registered public accounting firm                   *
                               
      23.2   Consent of Honigman LLP (included in Exhibit 5.1)                   *
                   
      24.1   Power of Attorney (included on the signature page of the Registration Statement)                   *
                   
      99.1   BioXcel Therapeutics, Inc. 2020 Incentive Award Plan   10-Q   001-38410   8-14-2020   10.1    
                   
      99.2   BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan   10-Q   001-38410   8-14-2020   10.2    
                               
      107.1   Filing Fee Table                   *

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut, on this 4th day of April, 2025.

     

    BioXcel Therapeutics, Inc.  
         
    By  /s/ Vimal Mehta  
      Vimal Mehta  
      Chief Executive Officer, President and Director  

     

    POWER OF ATTORNEY

     

    Each of the undersigned officers and directors of the registrant hereby severally constitutes and appoints Vimal Mehta, Ph.D. and Richard Steinhart, and each of them singly (with full power to each of them to act alone), as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them, for him or her and in his or her name, place and stead, and in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Vimal Mehta, Ph.D.   Chief Executive Officer, President and Director    April 4, 2025
    Vimal Mehta, Ph.D.   (principal executive officer)    
             
    /s/ Richard Steinhart   Chief Financial Officer    April 4, 2025
    Richard Steinhart   (principal financial officer and principal accounting officer)    
             
    /s/ Peter Mueller, Ph.D.   Chairman of the Board of Directors    April 4, 2025
    Peter Mueller, Ph.D.        
             
    /s/ June Bray   Director    April 4, 2025
    June Bray        
             
    /s/ Sandeep Laumas, M.D.   Director    April 4, 2025
    Sandeep Laumas, M.D.        
             
    /s/ Michael Miller   Director    April 4, 2025
    Michael Miller        
             
    /s/ Michal Votruba, M.D., Ph.D.   Director    April 4, 2025
    Michal Votruba, M.D., Ph.D.        

     

    /s/ David Mack   Director    April 4, 2025
    David Mack        

     

    /s/ Rajiv Patni, M.D.   Director    April 4, 2025
    Rajiv Patni, M.D.        

     

     

     

    Get the next $BTAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTAI

    DatePrice TargetRatingAnalyst
    2/21/2024$9.00 → $4.00Buy → Neutral
    UBS
    8/15/2023$40.00 → $4.00Buy → Neutral
    Mizuho
    7/17/2023Buy → Neutral
    Guggenheim
    3/10/2023$20.00 → $22.00Buy → Hold
    Jefferies
    12/1/2022$16.00Sell → Neutral
    Goldman
    7/7/2022$19.00Buy
    Mizuho
    4/6/2022$80.00Buy
    BofA Securities
    2/16/2022$88.00 → $25.00Buy
    UBS
    More analyst ratings

    $BTAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioXcel Therapeutics downgraded by UBS with a new price target

      UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously

      2/21/24 8:16:51 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously

      8/15/23 7:17:23 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics downgraded by Guggenheim

      Guggenheim downgraded BioXcel Therapeutics from Buy to Neutral

      7/17/23 7:16:08 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 20% to 10,158 units (SEC Form 4)

      4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

      5/1/25 7:23:09 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by O'Neill Vincent

      4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

      4/1/25 6:08:53 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and President Mehta Vimal

      4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

      4/1/25 6:08:00 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

      SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

      9/10/24 10:47:52 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by BioXcel Therapeutics Inc. (Amendment)

      SC 13D/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

      6/6/24 8:29:42 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BioXcel Therapeutics Inc. (Amendment)

      SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

      2/9/24 8:35:57 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Financials

    Live finance-specific insights

    See more
    • BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

      Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

      3/27/25 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

      Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's dementia Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. "Our focus continues to be the clinical development of BXCL501," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "We are advancing our SERENITY At-Home trial to pursue the near-term growth opportunity for t

      11/14/24 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

      NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2024 financial results on Thursday, November 14, 2024, before the open of the U.S. financial markets. The Company's management team will also host a conference call and webcast at 8:00 AM ET that day to discuss these results and provide a general business update. Conference Call and Webcast DetailsDate/Time:Thursday, November 14, 2024, at 8:00 AM ETParticipant Dial-In:877-407-5795 / 201-689-8722  The webcast link will be accessibl

      11/8/24 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting NEW HAVEN, Conn., May 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the first quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with b

      5/12/25 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – The potential for artificial intelligence (AI) in healthcare is still unfolding, both for patients and providers. A recent report from Deloitte found that 71% of healthcare industry leaders expect improved profitability this year, and it comes with rising AI implementation in care. At a global level, the World Health Organization (WHO) recently launched a new AI collaboration center for healthcare through the Digital Ethics Center at Delft University of Technology in the Netherlands, while the World Economic Forum (WEF) is championing prior

      4/16/25 8:58:00 AM ET
      $AMST
      $BTAI
      $PLTR
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

      Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

      3/27/25 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioXcel Therapeutics Inc.

      10-Q - BioXcel Therapeutics, Inc. (0001720893) (Filer)

      5/12/25 9:00:36 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

      5/12/25 7:15:26 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by BioXcel Therapeutics Inc.

      S-8 - BioXcel Therapeutics, Inc. (0001720893) (Filer)

      4/4/25 4:16:14 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

      Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company's strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O'Neill, M.D., Senior Vice

      12/11/23 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

      NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. "We are pleased to welcome Mike to our Board and believe his deep commercial and market access expertise will be

      7/5/22 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

      NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO). "We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "With over 25 years of commercial and industry exper

      1/19/22 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

      Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

      4/6/22 2:18:32 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care